Rinri Therapeutics
Rinri Therapeutics is a clinical-stage biotechnology company developing regenerative cell therapies for the treatment of sensorineural hearing loss. Its primary product portfolio includes Rincell-1, a therapy currently undergoing first-in-human clinical trials to restore neural health and hearing function. The company targets patients suffering from hearing loss by focusing on the restoration of auditory nerve connections.
Biotechnology
Healthcare
Regenerative Medicine
Funding summary
- Total raised
- €11.6M
- Funding rounds
- 1
Investors in Rinri Therapeutics
Investors on record for Rinri Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Rinri Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors